The antiserum was produced against synthesized peptide derived from human PDGFR beta around the phosphorylation site of Tyr1021. AA range:991-1040

Phospho-PDGFR-β (Y1021) Polyclonal Antibody detects endogenous levels of PDGFR-β protein only when phosphorylated at Y1021.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):NDyII

PDGFRB PDGFR PDGFR1

Platelet-derived growth factor receptor beta

PDGFRB ;
PDGFR ;
PDGFR1 ;
Platelet-derived growth factor receptor beta ;
PDGF-R-beta ;
PDGFR-beta ;
Beta platelet-derived growth factor receptor ;
Beta-type platelet-derived growth factor receptor ;
CD140 antigen-like family member B ;
Platelet-deri

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer , composed of both platelet-derived growth factor receptor alpha and beta polypeptides. This gene is flanked on chromosome 5 by the genes for granulocyte-macrophage colony-stimulating factor and macrophage-colony stimulating factor receptor; all three genes may be implicated in the 5-q syndrome. A translocation between chromosomes 5 and 12 , that fuses this gene to that of the translocation , ETV6 , leukemia gene , results in chronic myeloproliferative disorder with eosinophilia. [provided by RefSeq , Jul 2008] ,

Catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. ,Disease:A chromosomal aberration involving PDGFRB is a cause in many instances of chronic myeloproliferative disorder with eosinophilia (MPE) [MIM:131440]. Translocation t (5;12) with ETV6 on chromosome 12 creating an PDGFRB-ETV6 fusion protein. ,Disease:A chromosomal aberration involving PDGFRB is found in a form of chronic myelomonocytic leukemia (CMML) . Translocation t (5;12) (q33;p13) with EVT6/TEL. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML) . ,Disease:A chromosomal aberration involving PDGFRB may be a cause of acute myelogenous leukemia. Translocation t (5;14) (q33;q32) with TRIP11. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia. ,Disease:A chromosomal aberration involving PDGFRB may be a cause of juvenile myelomonocytic leukemia. Translocation t (5;17) (q33;p11.2) with SPECC1. ,Disease:A chromosomal aberration involving PDGFRB may be the cause of a myeloproliferative disorder (MBD) associated with eosinophilia. Translocation t (1;5) (q23;q33) that forms a PDE4DIP-PDGFRB fusion protein. ,Function:Receptor that binds specifically to PDGFB and PDGFD and has a tyrosine-protein kinase activity. Phosphorylates Tyr residues at the C-terminus of PTPN11 creating a binding site for the SH2 domain of GRB2. ,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. ,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. ,similarity:Contains 1 protein kinase domain. ,similarity:Contains 5 Ig-like C2-type (immunoglobulin-like) domains. ,subunit:Homodimer , and heterodimer with PDGFRA. Interacts with APS. The autophosphorylated form interacts directly with SHB and with PIK3C2B , maybe indirectly. ,

Cell membrane; Single-pass type I membrane protein. Cytoplasmic vesicle. Lysosome lumen. After ligand binding , the autophosphorylated receptor is ubiquitinated and internalized , leading to its degradation.

>>EGFR tyrosine kinase inhibitor resistance ;
>>MAPK signaling pathway ;
>>Ras signaling pathway ;
>>Rap1 signaling pathway ;
>>Calcium signaling pathway ;
>>Phospholipase D signaling pathway ;
>>PI3K-Akt signaling pathway ;
>>Focal adhesion ;
>>Gap junction ;
>>JAK-STAT signaling pathway ;
>>Regulation of actin cytoskeleton ;
>>Human papillomavirus infection ;
>>Pathways in cancer ;
>>MicroRNAs in cancer ;
>>Glioma ;
>>Prostate cancer ;
>>Melanoma ;
>>Central carbon metabolism in cancer ;
>>Choline metabolism in cancer